RBC Capital analyst Brian Abrahams downgraded Neumora Therapeutics (NMRA) to Sector Perform from Outperform with a price target of $4, down from $29.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Neumora Therapeutics Inc trading resumes
- Neumora Therapeutics Inc trading halted, volatility trading pause
- Neumora trial failure a ‘big blow’ to bull case, says Stifel
- Morning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint
- Neumora down 82% after saying navacaprant did not meet primary endpoint